Veterans Affairs announces new MDMA clinical trial; Psilocybin’s antidepressant effects are both rapid and long-lasting
Plus: Psychedelic trips leave traces in speech through vocal “jitter” and “shimmer;" Scientists pair intravenous ketamine with drug targeting opioid receptors to enhance antidepressant effects
External link. We are not responsible for the content.
Read more ↗More From The Microdose (Berkeley)
What’s stopping psychedelic therapy in China? 5 Questions with medical ethicist Jennifer Docherty
Docherty discusses her interviews about psychedelic end-of-life care with clinicians in Hong Kong.
What is an “embedded” brain? Johnson & Johnson plans to invest in “neuroplastogen” company Delix; and University of Miami gifts Trump Administration accelerated path to research ibogaine
Plus: Oregon psilocybin program “generally safe,” according to new study, and New Mexico begins accepting psilocybin ...
What’s the difference between recreational and therapeutic psychedelic use? 5 Questions with experimental psychologist Harriet de Wit
De Wit discusses the difficulty of finding out what a drug does, outside of its context.
Latest News
Why Most Drugs Fail, and Why Virtual Tissue Models Beat Virtual Cell Models
Welcome back to Business Trip by PsyMed Ventures, a podcast exploring the future of mental health & wellness!
Ibogaine’s Momentum Is Real. So Is the Safety Gap Nobody’s Solving.
Recent reporting, has documented a string of serious adverse events at overseas psychedelic clinics such as cardiac d...
Was Carlos Castaneda Among the First Psychedelic Grifters?
Author Carlos Castaneda built a fortune on a fabricated Indigenous lineage. A new biography shows how his blueprint s...
University of Miami’s Gift of 1994 Ibogaine IND to HHS Sets a Standard for Open Science
Washington, D.C., August 25, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS)has welcomed the ...
Who Gets to Heal?
A donor gift with no diagnosis requirement forced a debate inside Thank You Life. Its executive director asks whether...
Weekly Psychedelic Policy Briefing: August 23, 2026
Oregon's psilocybin program posted its first real-world outcome data this week, just as regulators move on fee increa...